» Articles » PMID: 26490346

Sulforaphane Attenuates the Development of Atherosclerosis and Improves Endothelial Dysfunction in Hypercholesterolemic Rabbits

Overview
Specialty Biology
Date 2015 Oct 23
PMID 26490346
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of the present work was to explore possible protective effects of sulforaphane (SFN) against atherosclerosis development and endothelial dysfunction in hypercholesterolemic rabbits. Rabbits were assigned to three groups of five: group I fed normal chow diet for four weeks, group II fed 1% high cholesterol diet (HCD) and group III fed HCD + SFN (0.25 mg/kg/day). Blood samples were collected for measurement of serum triglycerides (TGs), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), lactate dehydrogenase (LDH) and C-reactive protein (CRP). Aortic malondialdehyde (MDA), reduced glutathione (GSH), superoxide dismutase (SOD) and total nitrite/nitrate (NOx) were measured. Vascular reactivity and intima/media (I/M) ratio were analyzed. Nuclear factor-kappa B (NF-κB) activation in aortic endothelial cells was identified immunohistochemically. HCD induced significant increases in serum TGs, TC, LDL-C, LDH, and CRP, and aortic MDA and SOD. Moreover, HCD caused significant reductions in serum HDL-C, aortic GSH and NOx. SFN administration significantly decreased HCD-induced elevations in serum TC, LDL-C, CRP, and LDH. while significantly increased HDL-C and GSH levels and normalized aortic SOD and NOx. Additionally, SFN significantly improved rabbit aortic endothelium-dependent relaxation to acetylcholine. Moreover, SFN significantly reduced the elevation in I/M ratio. This effect was confirmed by aortic histopathologic examination. The expression of NF-κB in aortic tissue showed a marked reduction upon treatment with SFN. In conclusion, this study reveals that SFN has the ability to ameliorate HCD-induced atherosclerotic lesions progression and vascular dysfunction, possibly via its lipid-lowering and antioxidant effects and suppression of NF-κB-mediated inflammation.

Citing Articles

Protective Effects of Sulforaphane Preventing Inflammation and Oxidative Stress to Enhance Metabolic Health: A Narrative Review.

Alves I, Araujo E, Dalgaard L, Singh S, Borsheim E, Carvalho E Nutrients. 2025; 17(3).

PMID: 39940284 PMC: 11821257. DOI: 10.3390/nu17030428.


Sulforaphane acutely activates multiple starvation response pathways.

Plafker K, Georgescu C, Pezant N, Pranay A, Plafker S Front Nutr. 2025; 11:1485466.

PMID: 39867556 PMC: 11758633. DOI: 10.3389/fnut.2024.1485466.


New horizons for promising influences of sulforaphane in the management of metabolic syndrome: a mechanistic review.

Masoumvand M, Ramezani E, Eshaghi Milasi Y, Baradaran Rahimi V, Askari V Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39702599 DOI: 10.1007/s00210-024-03706-3.


The effect of sulforaphane on markers of inflammation and metabolism in virally suppressed HIV patients.

Giron J, Smiarowski L, Katz J Front Nutr. 2024; 11:1357906.

PMID: 39539366 PMC: 11557404. DOI: 10.3389/fnut.2024.1357906.


Nrf2 Connects Cellular Autophagy and Vascular Senescence in Atherosclerosis: A Mini-Review.

Wai K, Low L, Goh B, Yap W J Lipid Atheroscler. 2024; 13(3):292-305.

PMID: 39355399 PMC: 11439754. DOI: 10.12997/jla.2024.13.3.292.


References
1.
FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

2.
Steinberg D, Parthasarathy S, Carew T, Khoo J, Witztum J . Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989; 320(14):915-24. DOI: 10.1056/NEJM198904063201407. View

3.
Witztum J, Steinberg D . Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88(6):1785-92. PMC: 295745. DOI: 10.1172/JCI115499. View

4.
Fahey J, Talalay P . Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol. 1999; 37(9-10):973-9. DOI: 10.1016/s0278-6915(99)00082-4. View

5.
CASTELLI W . Cardiovascular disease in women. Am J Obstet Gynecol. 1988; 158(6 Pt 2):1553-60, 1566-7. DOI: 10.1016/0002-9378(88)90189-5. View